You Are Now Leaving Mounjaro.lilly.com
You've clicked on a link for a third-party site, which Lilly USA, LLC does not control, influence, or endorse. Lilly is not responsible for any content on this third-party site, including the privacy policy. Click “Continue” to leave site or “Go Back” to return to Mounjaro.lilly.com.
*In studies with or without diabetes medications, 75% to 90% of people taking Mounjaro reached an A1C of less than 7%, with an average starting A1C of 7.9% to 8.6% across the 5-mg, 10-mg, and 15-mg doses.
†Study results were measured at 40 and 52 weeks.
Select Safety Information
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
Mounjaro is not a weight loss drug.
‡Individual results may vary. In studies with or without other diabetes medications, weight loss in adults ranged from 12 lb (5 mg) to 25 lb (15 mg).
Select Safety Information
Severe stomach problems. Stomach problems, sometimes severe, have been reported with Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
In clinical studies, Mounjaro was compared to some other medicines for type 2 diabetes.
Mounjaro A1C results
In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to Ozempic 1 mg in 1879 adults with type 2 diabetes who were also taking metformin and had a starting A1C of 8.3%.
For people taking Mounjaro, their A1C was lowered on average by 2.0% on the 5-mg dose, 2.2% on the 10-mg dose, and 2.3% on the 15-mg dose. For people taking the Ozempic 1-mg dose, their A1C was lowered on average by 1.9%.
In a 52-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to titrated Tresiba, a basal insulin, in 1444 adults with type 2 diabetes who were also taking metformin with or without another oral diabetes medication. They had an average starting A1C of 8.1 to 8.2%. At the end of the study, 26% of people on Tresiba met the blood sugar goal (or target). The average daily dose of Tresiba was 49 units per day by the end of the study.
For people taking Mounjaro, their A1C was lowered by 1.9% on the 5-mg dose, 2.0% on the 10-mg dose, and 2.1% on the 15-mg dose. For people taking Tresiba, their A1C was lowered by 1.3%.
In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to placebo in 475 adults with type 2 diabetes who were also taking insulin glargine. Some study participants were also taking metformin. They had a starting A1C of 8.2% to 8.4%.
Select Safety Information
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness, and feeling jittery.
For people taking Mounjaro and insulin glargine, their A1C was lowered by 2.1% on the 5-mg dose, 2.4% on the 10-mg dose, and 2.3% on the 15-mg dose. For people taking placebo and insulin glargine, their A1C was lowered by 0.9%.
Mounjaro weight results
*Mounjaro is not a weight loss drug.
Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to Ozempic 1 mg. The average starting weight was between 204 to 209 pounds.
People taking Mounjaro saw an average weight loss of 17 pounds on the 5-mg dose, 21 pounds on the 10-mg dose, and 25 pounds on the 15-mg dose. Those taking the Ozempic 1-mg dose saw an average weight loss of 13 pounds.
*Mounjaro is not a weight loss drug.
Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to titrated Tresiba, a basal insulin commonly associated with weight gain. All participants also took metformin with or without another oral diabetes medication. The average starting weight was between 207 to 209 pounds.
Those taking Mounjaro saw an average weight loss of 15 pounds on the 5-mg dose, 21 pounds on the 10-mg dose, and 25 pounds on the 15-mg dose. Those taking Tresiba saw an average weight gain of 4 pounds.
*Mounjaro is not a weight loss drug.
Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to placebo. Study participants were also taking insulin glargine, a medication commonly associated with weight gain. Some study participants were also taking metformin. The average starting weight was between 208 to 212 pounds.
Select Safety Information
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin.Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness, and feeling jittery.
Those taking Mounjaro plus insulin glargine saw an average weight loss of 12 pounds on the 5-mg dose, 17 pounds on the 10-mg dose, and 19 pounds on the 15-mg dose. Those taking insulin glargine and placebo gained an average of 4 pounds.
Select Safety Information
Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.
*Along with diet and exercise.
We want to help. You may pay as little as $25 for a 1-month or 3-month prescription with the Mounjaro Savings Card. * †
*For eligible commercially insured patients with Mounjaro coverage. Governmental beneficiaries excluded, terms and conditions apply.
†One month is defined as 28 days and 4 pens. Three months is defined as 84 days and up to 12 pens.
By enrolling in and using the Mounjaro Savings Card Program ("Program") and using the Mounjaro Savings Card ("Card"), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:
Card Eligibility:
Card Terms and Conditions
For patients with commercial drug insurance coverage for Mounjaro: You must have commercial drug insurance that covers Mounjaro®(tirzepatide) and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill of Mounjaro. One month is defined as 28-days and up to 4 pens; 2 months is defined as 56 days and up to 8 pens; 3 months is defined as 84 days and up to 12 pens. Card savings are subject to a maximum monthly savings of up to $150 per 1-month prescription, $300 per 2-month prescription, or $450 per 3-month prescription fill and separate maximum annual savings of up to $1,950 per calendar year. Card may be used for a maximum of up to 13 prescription fills per calendar year. Participation in the Program requires a valid patient HIPAA authorization. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.
For patients with commercial drug insurance who do not have coverage for Mounjaro: You must have commercial drug insurance that does not cover Mounjaro and a prescription for an approved use consistent with FDA-approved product labeling to obtain savings of up to $473 off your 1-month prescription fill of Mounjaro. Month is defined as 28-days and up to 4 pens. Card savings are subject to a maximum monthly savings of up to $473 and a separate maximum annual savings of up to $3,311 per calendar year. Card may be used for a maximum of up to 7 prescription fills per calendar year. Participation in the Program requires a valid patient HIPAA authorization. Subject to Lilly's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 06/30/2025.
If you have an insurance plan that is participating in an alternate funding program ("AFP") that requires you to apply to the Mounjaro Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Mounjaro, you are not eligible for and are prohibited from using the Mounjaro Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Mounjaro Savings Card Program. You agree to inform the Mounjaro Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the applicable monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Mounjaro, only allows partial coverage for Mounjaro, removes coverage for Mounjaro and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Mounjaro, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Mounjaro. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Mounjaro Savings Card and agree to call the Mounjaro Savings Card Program at 1-844-805-5807 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Mounjaro. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Mounjaro Savings Card Program may change from time to time; the most current version can be found at https://www.mounjaro.lilly.com/savings-resources#savings. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025 for patients with commercial drug insurance with coverage for Mounjaro and on 06/30/2025 for patients with commercial drug insurance who do not have coverage for Mounjaro.
By enrolling in and using the Mounjaro Savings Card Program ("Program") and using the Mounjaro Savings Card ("Card"), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:
Card Eligibility:
Card Terms and Conditions
For patients with commercial drug insurance coverage for Mounjaro: You must have commercial drug insurance that covers Mounjaro®(tirzepatide) and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill of Mounjaro. One month is defined as 28-days and up to 4 pens; 2 months is defined as 56 days and up to 8 pens; 3 months is defined as 84 days and up to 12 pens. Card savings are subject to a maximum monthly savings of up to $150 per 1-month prescription, $300 per 2-month prescription, or $450 per 3-month prescription fill and separate maximum annual savings of up to $1,950 per calendar year. Card may be used for a maximum of up to 13 prescription fills per calendar year. Participation in the Program requires a valid patient HIPAA authorization. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.
For patients with commercial drug insurance who do not have coverage for Mounjaro: You must have commercial drug insurance that does not cover Mounjaro and a prescription for an approved use consistent with FDA-approved product labeling to obtain savings of up to $473 off your 1-month prescription fill of Mounjaro. Month is defined as 28-days and up to 4 pens. Card savings are subject to a maximum monthly savings of up to $473 and a separate maximum annual savings of up to $3,311 per calendar year. Card may be used for a maximum of up to 7 prescription fills per calendar year. Participation in the Program requires a valid patient HIPAA authorization. Subject to Lilly's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 06/30/2025.
Additional Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program ("AFP") that requires you to apply to the Mounjaro Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Mounjaro, you are not eligible for and are prohibited from using the Mounjaro Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Mounjaro Savings Card Program. You agree to inform the Mounjaro Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the applicable monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Mounjaro, only allows partial coverage for Mounjaro, removes coverage for Mounjaro and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Mounjaro, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Mounjaro. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Mounjaro Savings Card and agree to call the Mounjaro Savings Card Program at 1-844-805-5807 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Mounjaro. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card.THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Mounjaro Savings Card Program may change from time to time; the most current version can be found at https://www.mounjaro.lilly.com/savings-resources#savings. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025 for patients with commercial drug insurance with coverage for Mounjaro and on 06/30/2025 for patients with commercial drug insurance who do not have coverage for Mounjaro.
You Are Now Leaving Mounjaro.lilly.com
You've clicked on a link for a third-party site, which Lilly USA, LLC does not control, influence, or endorse. Lilly is not responsible for any content on this third-party site, including the privacy policy. Click “Continue” to leave site or “Go Back” to return to Mounjaro.lilly.com.
Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
Mounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Mounjaro may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery.
Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.
Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools.
The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Mounjaro is a prescription medicine. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.
This summary provides basic information about Mounjaro but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you.
TR CON CBS 14SEP2022
Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.